{
    "info": {
        "nct_id": "NCT04404088",
        "official_title": "A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma",
        "inclusion_criteria": "* Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a\n* Have had no prior systemic treatment for lymphoma\n* Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)\n* Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment\n* Stage III or IV disease\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Absolute neutrophil count (ANC) >= 1,000/mm^3, independent of growth factor support (within 28 days prior to signing informed consent)\n* Platelet counts >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement with lymphoma, independent of transfusion support in either situation (within 28 days prior to signing informed consent)\n* Hemoglobin > 8 g/dL, independent of transfusion support (within 28 days prior to signing informed consent)\n* Serum aspartate transaminase (AST) or alanine transaminase (ALT) < 2 x upper limit of normal (ULN) (within 28 days prior to signing informed consent)\n* Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula (within 28 days prior to signing informed consent)\n* Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL (within 28 days prior to signing informed consent)\n* Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time (PTT) < 1.5 x ULN (within 28 days prior to signing informed consent)\n* Must be able to adhere to the study visit schedule and other protocol requirements\n* Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study (females of childbearing potential: must either completely abstain from heterosexual sexual conduct or must use 2 methods of reliable contraception, 1 highly effective [intrauterine device, birth control pills, hormonal patches, injections, vaginal rings, or implants] and at least 1 additional method [condom, diaphragm, cervical cap] of birth control). Reliable contraceptive methods must be started at least 4 weeks before lenalidomide, and continued for at least 4 weeks after last dose of lenalidomide. Males who are sexually active must be practicing complete abstinence or agree to a condom during sexual contact with a pregnant female or female of child bearing potential. Men must agree to not donate sperm during and after the study. For females, these restrictions apply at least 4 weeks before study treatment, during the period of therapy and for 1 month after the last dose of study drug. For males, these restrictions apply during the period of therapy and for 3 months after the last dose of study drug\n* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study\n\n  * Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program\n* Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study\n* All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known active central nervous system lymphoma or leptomeningeal disease, except subjects with a history of central nervous system lymphoma treated and in remission > 6 months\n* Evidence of diffuse large B-cell transformation\n* Grade 3b FL\n* Any prior history of other malignancy besides FL or marginal zone lymphoma, unless the patient has been free of disease for >= 5 years and felt to be at low risk for recurrence by the treating physician, except:\n\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated cervical carcinoma in situ without evidence of disease\n* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib or lenalidomide capsules, or put the study outcomes at undue risk\n* Known history of human immunodeficiency virus (HIV), or active hepatitis C Virus, or active hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed John Cunningham (JC) virus infection\n\n  * Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. Subjects with a history of Hepatitis C who received antiviral treatment are eligible as long as PCR is negative\n* Concurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of > 10 mg/day of prednisone) within 28 days of the first dose of study drug\n* Known anaphylaxis or immunoglobulin (Ig) E-mediated hypersensitivity to murine proteins or to any component of acalabrutinib, lenalidomide and/or rituximab\n* Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon). If patients have been on warfarin or equivalent vitamin K antagonists in the past, they will not be eligible if administered within 30 days of the first dose of study drug\n* Requires chronic treatment with strong CYP3A inhibitors, for a list of strong CYP3A inhibitors. If patients have been on a strong CYP3A inhibitor in the past, they will not be eligible if the CYP3A inhibitor was administered within 7 days of the first dose of study drug\n* Requires chronic treatment with strong CYP3A inducers, for a list of strong CYP3A inducers. If patients have been on a strong CYP3A inducer in the past, they will not be eligible if the CYP3A inducer was administered within 7 days of the first dose of study drug\n* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association functional classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study\n* Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block, type II AV block, or 3rd degree block\n* Active bleeding or known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia\n* History of stroke or intracranial hemorrhage within 6 months prior to study entry\n* Vaccinated with live, attenuated vaccines within 4 weeks of study entry\n* Lactating or pregnant subjects\n* Administration of any investigational agent within 28 days of first dose of study drug\n* Patients who have undergone major surgery within 28 days or minor surgery within 3 days of first dose of study drug\n* Patients taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 10 mg/day prednisone (over these 4 weeks)\n* Life expectancy < 6 months\n* Neuropathy > grade 1\n* Prior exposure to lenalidomide or to a BCR inhibitor, independently from indication\n* Patient who require treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole), and are unable to switch to H2-receptor antagonists\n* Patients who have difficulty with or are unable to swallow oral medication, or have disease significantly affecting gastrointestinal function that would limit absorption of oral medication\n* Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)\n* Known history of deep vein thrombosis or pulmonary embolism\n* Known history of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) or drug rash with eosinophilia and systemic symptoms (DRESS)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time (PTT) < 1.5 x ULN (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x ULN",
                    "criterion": "prothrombin time (PT)/international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) < 1.5 x ULN",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stage III or IV disease",
            "criterions": [
                {
                    "exact_snippets": "Stage III or IV disease",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must be able to adhere to the study visit schedule and other protocol requirements",
            "criterions": [
                {
                    "exact_snippets": "Must be able to adhere to the study visit schedule",
                    "criterion": "ability to adhere to study visit schedule",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Must be able to adhere to ... other protocol requirements",
                    "criterion": "ability to adhere to protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program",
            "criterions": [
                {
                    "exact_snippets": "Females of reproductive potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must adhere to the scheduled pregnancy testing",
                    "criterion": "adherence to scheduled pregnancy testing",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as required in the Revlimid Risk Evaluation and Mitigation Strategies (REMS) program",
                    "criterion": "compliance with Revlimid REMS program requirements",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin > 8 g/dL, independent of transfusion support (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin > 8 g/dL",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "independent of transfusion support",
                    "criterion": "transfusion support",
                    "requirements": [
                        {
                            "requirement_type": "independence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 28 days prior to signing informed consent",
                    "criterion": "hemoglobin measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to signing informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "Gilbert's syndrome",
                                "documented liver involvement with lymphoma",
                                "bilirubin of non-hepatic origin"
                            ]
                        },
                        {
                            "requirement_type": "quantity (if exception applies)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test at screening",
                    "criterion": "serum (beta-hCG) pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are pregnant ... are ineligible for this study",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... breastfeeding are ineligible for this study",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have had no prior systemic treatment for lymphoma",
            "criterions": [
                {
                    "exact_snippets": "no prior systemic treatment for lymphoma",
                    "criterion": "prior systemic treatment for lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study",
            "criterions": [
                {
                    "exact_snippets": "Sign ... an informed consent document",
                    "criterion": "informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "indicating that they understand the purpose of and procedures required for the study, including biomarkers",
                    "criterion": "understanding of study purpose and procedures",
                    "requirements": [
                        {
                            "requirement_type": "understanding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to participate in the study",
                    "criterion": "willingness to participate",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1,000/mm^3, independent of growth factor support (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1,000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "independent of growth factor support",
                    "criterion": "growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "independence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 28 days prior to signing informed consent",
                    "criterion": "timing of laboratory value",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to signing informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment",
            "criterions": [
                {
                    "exact_snippets": "Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment",
                    "criterion": "GELF criteria for initiation of treatment",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed CD20 positive (+) follicular lymphoma",
                    "criterion": "follicular lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "CD20 positive (+)",
                    "criterion": "CD20 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 1, 2, or 3a",
                    "criterion": "follicular lymphoma grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "1",
                                "2",
                                "3a"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All study participants must be registered into the mandatory Revlimid REMS program, and be willing and able to comply with the requirements of the REMS program",
            "criterions": [
                {
                    "exact_snippets": "All study participants must be registered into the mandatory Revlimid REMS program",
                    "criterion": "Revlimid REMS program registration",
                    "requirements": [
                        {
                            "requirement_type": "registration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing and able to comply with the requirements of the REMS program",
                    "criterion": "willingness and ability to comply with REMS program requirements",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet counts >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement with lymphoma, independent of transfusion support in either situation (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Platelet counts >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement with lymphoma, independent of transfusion support in either situation (within 28 days prior to signing informed consent)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 100000,
                                        "unit": "mm^3"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity_with_bone_marrow_involvement",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 50000,
                                        "unit": "mm^3"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "transfusion_independence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": "within 28 days prior to signing informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bi-dimensionally measurable disease, with at least one mass lesion >= 2 cm in longest diameter by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)",
            "criterions": [
                {
                    "exact_snippets": "Bi-dimensionally measurable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "bi-dimensionally measurable"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one mass lesion >= 2 cm in longest diameter",
                    "criterion": "mass lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "dimension",
                            "expected_value": "longest"
                        }
                    ]
                },
                {
                    "exact_snippets": "by computed tomography (CT), positron emission tomography (PET)/CT, and/or magnetic resonance imaging (MRI)",
                    "criterion": "imaging modality",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "computed tomography (CT)",
                                "positron emission tomography (PET)/CT",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula (within 28 days prior to signing informed consent)",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "modified Cockcroft-Gault formula"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to signing informed consent"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Neuropathy > grade 1",
            "criterions": [
                {
                    "exact_snippets": "Neuropathy > grade 1",
                    "criterion": "neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of deep vein thrombosis or pulmonary embolism",
            "criterions": [
                {
                    "exact_snippets": "Known history of deep vein thrombosis",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of ... pulmonary embolism",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaccinated with live, attenuated vaccines within 4 weeks of study entry",
            "criterions": [
                {
                    "exact_snippets": "Vaccinated with live, attenuated vaccines within 4 weeks of study entry",
                    "criterion": "vaccination with live, attenuated vaccines",
                    "requirements": [
                        {
                            "requirement_type": "time since vaccination",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy < 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy < 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon). If patients have been on warfarin or equivalent vitamin K antagonists in the past, they will not be eligible if administered within 30 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)",
                    "criterion": "anticoagulation with warfarin or equivalent vitamin K antagonists",
                    "requirements": [
                        {
                            "requirement_type": "requirement for anticoagulation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "If patients have been on warfarin or equivalent vitamin K antagonists in the past, they will not be eligible if administered within 30 days of the first dose of study drug",
                    "criterion": "prior use of warfarin or equivalent vitamin K antagonists",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "lentigo maligna without evidence of disease",
                    "criterion": "lentigo maligna",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": "without evidence of disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of any investigational agent within 28 days of first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Administration of any investigational agent within 28 days of first dose of study drug",
                    "criterion": "administration of investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lactating or pregnant subjects",
            "criterions": [
                {
                    "exact_snippets": "Lactating or pregnant subjects",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Lactating or pregnant subjects",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant screening electrocardiogram (ECG) abnormalities including left bundle branch block, 2nd degree atrioventricular (AV) block, type II AV block, or 3rd degree block",
            "criterions": [
                {
                    "exact_snippets": "Significant screening electrocardiogram (ECG) abnormalities",
                    "criterion": "screening electrocardiogram (ECG) abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "left bundle branch block",
                    "criterion": "left bundle branch block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "2nd degree atrioventricular (AV) block",
                    "criterion": "2nd degree atrioventricular (AV) block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "type II AV block",
                    "criterion": "type II AV block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "3rd degree block",
                    "criterion": "3rd degree block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of > 10 mg/day of prednisone) within 28 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Concurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc.",
                    "criterion": "systemic immunosuppressant therapy",
                    "requirements": [
                        {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic administration glucocorticoid equivalent of > 10 mg/day of prednisone",
                    "criterion": "glucocorticoid administration",
                    "requirements": [
                        {
                            "requirement_type": "chronic administration",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 28 days of the first dose of study drug",
                    "criterion": "timing of therapy relative to study drug",
                    "requirements": [
                        {
                            "requirement_type": "within days before first dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of diffuse large B-cell transformation",
            "criterions": [
                {
                    "exact_snippets": "Evidence of diffuse large B-cell transformation",
                    "criterion": "diffuse large B-cell transformation",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 10 mg/day prednisone (over these 4 weeks)",
            "criterions": [
                {
                    "exact_snippets": "Patients taking corticosteroids during the last 4 weeks",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": "last 4 weeks"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless administered at a dose equivalent to < 10 mg/day prednisone (over these 4 weeks)",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg/day prednisone"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "over these 4 weeks"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of stroke or intracranial hemorrhage within 6 months prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 6 months prior to study entry",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intracranial hemorrhage within 6 months prior to study entry",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association functional classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "uncontrolled",
                                "symptomatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within 6 months of screening",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association functional classification",
                    "criterion": "cardiac disease (NYHA classification)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "class 3",
                                "class 4"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study",
                    "criterion": "atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "control and symptoms",
                            "expected_value": "controlled and asymptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV), or active hepatitis C Virus, or active hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed John Cunningham (JC) virus infection",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis C Virus",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B Virus infection",
                    "criterion": "hepatitis B virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "any uncontrolled active significant infection",
                    "criterion": "significant infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "including suspected or confirmed John Cunningham (JC) virus infection",
                    "criterion": "John Cunningham (JC) virus infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "suspected",
                                "confirmed"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have difficulty with or are unable to swallow oral medication, or have disease significantly affecting gastrointestinal function that would limit absorption of oral medication",
            "criterions": [
                {
                    "exact_snippets": "Patients who have difficulty with or are unable to swallow oral medication",
                    "criterion": "ability to swallow oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "disease significantly affecting gastrointestinal function that would limit absorption of oral medication",
                    "criterion": "gastrointestinal function affecting absorption of oral medication",
                    "requirements": [
                        {
                            "requirement_type": "functionality",
                            "expected_value": "sufficient to allow absorption of oral medication"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient who require treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole), and are unable to switch to H2-receptor antagonists",
            "criterions": [
                {
                    "exact_snippets": "Patient who require treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole)",
                    "criterion": "proton pump inhibitor treatment requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement for treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are unable to switch to H2-receptor antagonists",
                    "criterion": "ability to switch to H2-receptor antagonists",
                    "requirements": [
                        {
                            "requirement_type": "ability to switch",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active bleeding or known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia",
            "criterions": [
                {
                    "exact_snippets": "Active bleeding",
                    "criterion": "active bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known bleeding diathesis (e.g., von Willebrand's disease)",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hemophilia",
                    "criterion": "hemophilia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires chronic treatment with strong CYP3A inhibitors, for a list of strong CYP3A inhibitors. If patients have been on a strong CYP3A inhibitor in the past, they will not be eligible if the CYP3A inhibitor was administered within 7 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Requires chronic treatment with strong CYP3A inhibitors",
                    "criterion": "chronic treatment with strong CYP3A inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "If patients have been on a strong CYP3A inhibitor in the past, they will not be eligible if the CYP3A inhibitor was administered within 7 days of the first dose of study drug",
                    "criterion": "prior use of strong CYP3A inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequately treated cervical carcinoma in situ without evidence of disease",
            "criterions": [
                {
                    "exact_snippets": "Adequately treated cervical carcinoma in situ",
                    "criterion": "cervical carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of disease",
                    "criterion": "evidence of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires chronic treatment with strong CYP3A inducers, for a list of strong CYP3A inducers. If patients have been on a strong CYP3A inducer in the past, they will not be eligible if the CYP3A inducer was administered within 7 days of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Requires chronic treatment with strong CYP3A inducers",
                    "criterion": "chronic treatment with strong CYP3A inducers",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CYP3A inducer was administered within 7 days of the first dose of study drug",
                    "criterion": "administration of strong CYP3A inducer within 7 days before first dose of study drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib or lenalidomide capsules, or put the study outcomes at undue risk",
            "criterions": [
                {
                    "exact_snippets": "Any life-threatening illness, medical condition, or organ system dysfunction",
                    "criterion": "life-threatening illness, medical condition, or organ system dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "which, in the investigator's opinion, could compromise the subject's safety",
                    "criterion": "risk to subject's safety",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "interfere with the absorption or metabolism of acalabrutinib or lenalidomide capsules",
                    "criterion": "interference with absorption or metabolism of acalabrutinib or lenalidomide",
                    "requirements": [
                        {
                            "requirement_type": "interference",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "put the study outcomes at undue risk",
                    "criterion": "risk to study outcomes",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active central nervous system lymphoma or leptomeningeal disease, except subjects with a history of central nervous system lymphoma treated and in remission > 6 months",
            "criterions": [
                {
                    "exact_snippets": "Known active central nervous system lymphoma",
                    "criterion": "central nervous system lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with a history of central nervous system lymphoma treated and in remission > 6 months",
                    "criterion": "central nervous system lymphoma (history, treated, remission)",
                    "requirements": [
                        {
                            "requirement_type": "history of disease",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        },
                        {
                            "requirement_type": "remission duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. Subjects with a history of Hepatitis C who received antiviral treatment are eligible as long as PCR is negative",
            "criterions": [
                {
                    "exact_snippets": "Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated",
                    "criterion": "hepatitis B reactivation prophylaxis adherence",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraindication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR)",
                    "criterion": "hepatitis B core antibody and surface antigen status with PCR",
                    "requirements": [
                        {
                            "requirement_type": "anti-HBc",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HbsAg",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "hepatitis B PCR",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded",
                    "criterion": "hepatitis B surface antigen or PCR positivity",
                    "requirements": [
                        {
                            "requirement_type": "HbsAg",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "hepatitis B PCR",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects who are hepatitis C antibody positive will need to have a negative PCR result",
                    "criterion": "hepatitis C antibody with PCR",
                    "requirements": [
                        {
                            "requirement_type": "hepatitis C antibody",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis C PCR",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Those who are hepatitis C PCR positive will be excluded",
                    "criterion": "hepatitis C PCR positivity",
                    "requirements": [
                        {
                            "requirement_type": "hepatitis C PCR",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with a history of Hepatitis C who received antiviral treatment are eligible as long as PCR is negative",
                    "criterion": "history of hepatitis C with antiviral treatment and PCR",
                    "requirements": [
                        {
                            "requirement_type": "history of hepatitis C",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "antiviral treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hepatitis C PCR",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to lenalidomide or to a BCR inhibitor, independently from indication",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to lenalidomide",
                    "criterion": "lenalidomide exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior exposure ... to a BCR inhibitor",
                    "criterion": "BCR inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled autoimmune hemolytic anemia (AIHA)",
                    "criterion": "autoimmune hemolytic anemia (AIHA)",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic thrombocytopenic purpura (ITP)",
                    "criterion": "idiopathic thrombocytopenic purpura (ITP)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior history of other malignancy besides FL or marginal zone lymphoma, unless the patient has been free of disease for >= 5 years and felt to be at low risk for recurrence by the treating physician, except:",
            "criterions": [
                {
                    "exact_snippets": "Any prior history of other malignancy besides FL or marginal zone lymphoma",
                    "criterion": "prior history of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the patient has been free of disease for >= 5 years",
                    "criterion": "disease-free interval for other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "felt to be at low risk for recurrence by the treating physician",
                    "criterion": "risk of recurrence for other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) or drug rash with eosinophilia and systemic symptoms (DRESS)",
            "criterions": [
                {
                    "exact_snippets": "Known history of Stevens-Johnson syndrome (SJS)",
                    "criterion": "Stevens-Johnson syndrome (SJS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of ... toxic epidermal necrolysis (TEN)",
                    "criterion": "toxic epidermal necrolysis (TEN)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known history of ... drug rash with eosinophilia and systemic symptoms (DRESS)",
                    "criterion": "drug rash with eosinophilia and systemic symptoms (DRESS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grade 3b FL",
            "criterions": [
                {
                    "exact_snippets": "Grade 3b FL",
                    "criterion": "follicular lymphoma (FL)",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "3b"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Serum aspartate transaminase (AST) or alanine transaminase (ALT) < 2 x upper limit of normal (ULN) (within 28 days prior to signing informed consent)",
            "criterions": [
                {
                    "exact_snippets": "Serum aspartate transaminase (AST) < 2 x upper limit of normal (ULN) (within 28 days prior to signing informed consent)",
                    "criterion": "serum aspartate transaminase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to signing informed consent"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine transaminase (ALT) < 2 x upper limit of normal (ULN) (within 28 days prior to signing informed consent)",
                    "criterion": "alanine transaminase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to signing informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study (females of childbearing potential: must either completely abstain from heterosexual sexual conduct or must use 2 methods of reliable contraception, 1 highly effective [intrauterine device, birth control pills, hormonal patches, injections, vaginal rings, or implants] and at least 1 additional method [condom, diaphragm, cervical cap] of birth control). Reliable contraceptive methods must be started at least 4 weeks before lenalidomide, and continued for at least 4 weeks after last dose of lenalidomide. Males who are sexually active must be practicing complete abstinence or agree to a condom during sexual contact with a pregnant female or female of child bearing potential. Men must agree to not donate sperm during and after the study. For females, these restrictions apply at least 4 weeks before study treatment, during the period of therapy and for 1 month after the last dose of study drug. For males, these restrictions apply during the period of therapy and for 3 months after the last dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential ... must be practicing a highly effective method of birth control during and after the study",
                    "criterion": "contraception use (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "use of highly effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "at least 4 weeks before study treatment",
                                "during the period of therapy",
                                "for 1 month after the last dose of study drug"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "females of childbearing potential: must either completely abstain from heterosexual sexual conduct or must use 2 methods of reliable contraception, 1 highly effective [intrauterine device, birth control pills, hormonal patches, injections, vaginal rings, or implants] and at least 1 additional method [condom, diaphragm, cervical cap] of birth control",
                    "criterion": "contraception method (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "abstinence or dual contraception",
                            "expected_value": [
                                "complete abstinence from heterosexual sexual conduct",
                                "use of 2 methods: 1 highly effective and 1 additional method"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Reliable contraceptive methods must be started at least 4 weeks before lenalidomide, and continued for at least 4 weeks after last dose of lenalidomide",
                    "criterion": "contraception timing (women of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "start time before lenalidomide",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "continue after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men who are sexually active must be practicing complete abstinence or agree to a condom during sexual contact with a pregnant female or female of child bearing potential",
                    "criterion": "contraception method (sexually active men)",
                    "requirements": [
                        {
                            "requirement_type": "abstinence or condom use",
                            "expected_value": [
                                "complete abstinence",
                                "condom use during sexual contact with a pregnant female or female of childbearing potential"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Men must agree to not donate sperm during and after the study",
                    "criterion": "sperm donation (men)",
                    "requirements": [
                        {
                            "requirement_type": "sperm donation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "For females, these restrictions apply at least 4 weeks before study treatment, during the period of therapy and for 1 month after the last dose of study drug. For males, these restrictions apply during the period of therapy and for 3 months after the last dose of study drug",
                    "criterion": "contraception restriction duration (by sex)",
                    "requirements": [
                        {
                            "requirement_type": "female restriction duration",
                            "expected_value": [
                                "at least 4 weeks before study treatment",
                                "during the period of therapy",
                                "for 1 month after the last dose of study drug"
                            ]
                        },
                        {
                            "requirement_type": "male restriction duration",
                            "expected_value": [
                                "during the period of therapy",
                                "for 3 months after the last dose of study drug"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Patients who have undergone major surgery within 28 days or minor surgery within 3 days of first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "undergone major surgery within 28 days of first dose of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery before first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undergone ... minor surgery within 3 days of first dose of study drug",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery before first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known anaphylaxis or immunoglobulin (Ig) E-mediated hypersensitivity to murine proteins or to any component of acalabrutinib, lenalidomide and/or rituximab",
            "criterions": [
                {
                    "exact_snippets": "Known anaphylaxis ... to murine proteins",
                    "criterion": "anaphylaxis to murine proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known anaphylaxis ... to any component of acalabrutinib, lenalidomide and/or rituximab",
                    "criterion": "anaphylaxis to any component of acalabrutinib, lenalidomide and/or rituximab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunoglobulin (Ig) E-mediated hypersensitivity to murine proteins",
                    "criterion": "IgE-mediated hypersensitivity to murine proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunoglobulin (Ig) E-mediated hypersensitivity to any component of acalabrutinib, lenalidomide and/or rituximab",
                    "criterion": "IgE-mediated hypersensitivity to any component of acalabrutinib, lenalidomide and/or rituximab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}